Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Ratio: 2010-2025

Historic Equity Ratio for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to 0.36.

  • Ani Pharmaceuticals' Equity Ratio fell 9.49% to 0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36, marking a year-over-year decrease of 9.49%. This contributed to the annual value of 0.31 for FY2024, which is 44.68% down from last year.
  • Ani Pharmaceuticals' Equity Ratio amounted to 0.36 in Q3 2025, which was up 10.45% from 0.33 recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Equity Ratio high stood at 0.57 for Q4 2023, and its period low was 0.31 during Q4 2024.
  • Moreover, its 3-year median value for Equity Ratio was 0.44 (2023), whereas its average is 0.43.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Equity Ratio soared by 32.82% in 2022, and later tumbled by 44.68% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.50 in 2021, then climbed by 5.72% to 0.53 in 2022, then climbed by 6.97% to 0.57 in 2023, then tumbled by 44.68% to 0.31 in 2024, then declined by 9.49% to 0.36 in 2025.
  • Its Equity Ratio was 0.36 in Q3 2025, compared to 0.33 in Q2 2025 and 0.32 in Q1 2025.